Back

ISPOR 2022 - Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research

May 15 - May 18, 2022 | National HarborMDUS

LARVOL is not affiliated with Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research and all trademarks, logos, and brand names are property of their respective owners

Showing 107 abstracts linked to Trials

P62 - Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in the Treatment of BRAF V600 Mutation-Positive Metastatic Melanoma

  • On-demand

P63 - Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma

  • On-demand

P59 - Comparative Efficacy and Safety of Ozanimod and Ponesimod for Relapsing Multiple Sclerosis: A Matching-Adjusted Indirect Comparison

  • On-demand

RWD12 - Randomized Clinical Trial Replication for Cardiovascular Outcomes of EMPA-Reg Trial: Retrospective Cohort Study

  • Poster

EE69 - Health and Economic Outcomes of Botulinum Toxin-a Products for Adult Patients with UPPER LIMB Spasticity in a Real-World Setting

  • Poster

EE35 - Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Vs. Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Non-Squamous, Advanced Non-Small Cell Lung Cancer in the USA

  • Poster